Related Experiment Video
Updated: Feb 23, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Small molecule T63 suppresses osteoporosis by modulating osteoblast differentiation via BMP and WNT signaling
Xiao-Li Zhao1, Jin-Jing Chen2, Guo-Ning Zhang1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Abstract:
Osteoporosis results from the imbalance between bone resorption and bone formation, and restoring the normal balance of bone remodeling is highly desirable for identification of better treatment. In this study, using a cell-based high-throughput screening model representing Runt-related transcription factor 2 (RUNX2) transcriptional activity, we identified a novel small-molecular-weight compound, T63, as an efficient up-regulator of osteogenesis. T63 increased the alkaline phosphatase (ALPL) activity and mineralization as well as gene expression of Alpl and other osteogenic marker genes in mouse osteoblasts and mesenchymal stem cell-like cells. Upon induction of osteoblast differentiation, T63 inhibited adipogenic differentiation in the pluripotent mesenchymal cells. Consistently, T63 up-regulated RUNX2 mRNA and protein levels, and knockdown of RUNX2 reduced the osteogenic role of T63. Mechanistically, T63 activated both BMPs and WNT/β-catenin signaling pathways. Inhibition of either signaling pathway with specific inhibitor suppressed T63-induced RUNX2 expression and the osteogenic phenotypes. Moreover, T63 markedly protected against bone mass loss in the ovariectomized and dexamethasone treated rat osteoporosis model. Collectively, our data demonstrate that T63 could be a promising drug candidate and deserves further development for potential therapeutics in osteoporosis.
Insights
A novel compound, T63, effectively promotes osteogenesis by up-regulating Runt-related transcription factor 2 (RUNX2) and bone formation. This compound shows promise for treating osteoporosis by restoring bone remodeling balance.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoporosis is characterized by an imbalance in bone remodeling, specifically between bone resorption and formation.
- Developing effective treatments to restore normal bone remodeling is crucial for managing osteoporosis.
Purpose of the Study:
- To identify novel small-molecule compounds that can promote osteogenesis.
- To investigate the therapeutic potential of a newly identified compound, T63, for osteoporosis treatment.
Main Methods:
- Utilized a cell-based high-throughput screening model for Runt-related transcription factor 2 (RUNX2) activity.
- Assessed T63's effects on osteoblast differentiation, mineralization, and gene expression in vitro.
- Evaluated T63's efficacy in established rat models of osteoporosis.
Main Results:
- T63 significantly increased alkaline phosphatase (ALPL) activity, mineralization, and osteogenic gene expression.
- T63 inhibited adipogenic differentiation and up-regulated RUNX2 at both mRNA and protein levels.
- T63 treatment protected against bone mass loss in ovariectomized and dexamethasone-induced osteoporosis models.
Conclusions:
- T63 is a potent up-regulator of osteogenesis, acting through RUNX2, BMPs, and WNT/β-catenin signaling pathways.
- T63 demonstrates significant therapeutic potential for osteoporosis and warrants further clinical development.
Related Concept Videos
TGF - β Signaling Pathway
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling
Osteoclasts in Bone Remodeling
Abnormal Proliferation

